The latest updates from AFAR.

Grantee in the News: David Holtzman on triple impact of ApoE4 in Nature.

Sep 22

Grantee in the News: David Holtzman on triple impact of ApoE4 in Nature. View MoreBACK

On September 20, 2017, Nature published research by 1995 Beeson Scholar David Holtzman, M.D. on two additional ways that the genetic variant ApoE4 impacts neourodeneration linked to Alzheimer’s Disease.

ApoE4 has long been understood to be a gentic risk factor for speeding up the development of brain plaques associated with Alzheimer’s.

In “ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy,” Holtzman and his co-authors discovered that ApoE4 also worsens tau tangles—another signature of the disease—as well as increases inflammation that kills brain cells.

This triple impact of ApoE4 discovered by Holtzman is already gaining significant attention in the field, as Northwestern University’s Robert Vasser tells Sciencenews:
“This paper is a tour de force… It’s a seminal study that’s going to be a landmark in the field” of Alzheimer’s research.

Read the Nature article here.

Read the related ScienceNews story here.

David Holtzman, M.D., is the Andrew B. and Gretchen P. Jones Professor and Chairman of Neurology, Professor of Developmental Biology, Associate Director of the Alzheimer’s Disease Research Center, and scientific director of the Hope Center for Neurological Disorders at Washington University in St. Louis. Dr. Holtzman has served on AFAR grant review committees and chaired the MetLife Foundation Awards for Medical Research in Alzheimer’s Disease selection committee, which AFAR managed.


For more on Alzheimer’s disease, check our AFAR’s expert-edited InfoAging Guide to Alzheimer’s Disease.